Fig. 6

Drug sensitivity analysis and in vitro validation. A Application of risk model to CCLE bladder cancer cell lines sorted by their risk score. B–D Invasion assay (B), wound healing assay (C) and colony formation assay (D) showing that T24 had relatively higher malignancy than RT112. E Volcano plot showing that cell lines with higher risk score were more sensitive to Talazoparib. F Dose-response growth curve of Talazoparib in T24 and RT112. G–I Validation of sensitivity to Talazoparib in vitro showing that T24 cell line with a higher risk score, was more sensitive to Talazoparib